Alkermes plc (ALKS) : Wednesdays money flow data in Alkermes plc (ALKS) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $9.71 million, whereas, $6.7 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.45, in favor of the bulls. The total money flow into the stock was $3.01 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $3.85 million. The total value of block trades done on upticks was $3.85 million. Alkermes plc (ALKS) fell $0.98 and traded at $48.81, down -1.97% for the day, over previous days close. On a weekly basis, the shares are -1.55% over the previous weeks close.
Alkermes plc has dropped 3.31% in the last five trading days, however, the shares have posted positive gains of 9.76% in the last 4 weeks. Alkermes plc is up 12.23% in the last 3-month period. Year-to-Date the stock performance stands at -38.51%.
Alkermes plc (ALKS) : Zacks Investment Research ranks Alkermes plc (ALKS) as 3, which is a Hold recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. The average broker rating of 4 research analysts is 1.83, which indicates as a Buy.
Alkermes plc (NASDAQ:ALKS): stock was range-bound between the intraday low of $48.2801 and the intraday high of $50.265 after having opened at $49.78 on Wednesdays session. The stock finally closed in the red at $49.78, a loss of -1.97%. The stock remained in the red for the whole trading day. The total traded volume was 672,185 shares. The stock failed to cross $50.265 in Wednesdays trading. The stocks closing price on Thursday was $49.79.
Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to meet unmet medical needs of patients in major therapeutic areas. The Company has a portfolio of more than 20 products and a clinical pipeline of product candidates being developed for the treatment of central nervous system (CNS) disorders, such as addiction, schizophrenia and depression. The Company is conducting clinical studies on new pharmaceutical products. These include Aripiprazole Lauroxil, ALKS 5461, ALKS 3831, ALKS 8700 and RDB 1419. The Companys main marketed products include RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION, AMPYRA/FAMPYRA, BYDUREON and VIVITROL.